Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
62.58 +0.03 (+0.05%) 11:33 ET [NYSE]
62.52 x 100 62.60 x 300
Realtime by (Cboe BZX)
62.52 x 100 62.60 x 300
Realtime 61.37 -1.18 (-1.89%) 09:30 ET
Quote Overview for Mon, Apr 7th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
60.61
Day High
65.28
Open 61.44
Previous Close 62.55 62.55
Volume 7,161,954 7,161,954
Avg Vol 7,325,716 7,325,716
Stochastic %K 6.21% 6.21%
Weighted Alpha -55.96 -55.96
5-Day Change -5.59 (-8.05%) -5.59 (-8.05%)
52-Week Range 60.66 - 148.15 60.66 - 148.15
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 280,695,136
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 42,108 M
  • Annual Income, $ 14,643 M
  • EBIT $ 18,609 M
  • EBITDA $ 21,380 M
  • 60-Month Beta 0.61
  • Price/Sales 7.15
  • Price/Cash Flow 17.29
  • Price/Book 14.47

Options Overview Details

View History
  • Implied Volatility 66.06% ( -0.84%)
  • Historical Volatility 43.70%
  • IV Percentile 99%
  • IV Rank 98.08%
  • IV High 66.90% on 04/04/25
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 0.78
  • Today's Volume 10,662
  • Volume Avg (30-Day) 37,241
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 447,293
  • Open Int (30-Day) 440,723

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.92
  • Number of Estimates 3
  • High Estimate 0.94
  • Low Estimate 0.90
  • Prior Year 0.83
  • Growth Rate Est. (year over year) +10.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.66 +5.26%
on 04/07/25
Period Open: 87.17
82.57 -22.67%
on 03/18/25
-23.32 (-26.75%)
since 03/07/25
3-Month
60.66 +5.26%
on 04/07/25
Period Open: 83.34
93.80 -31.93%
on 02/25/25
-19.49 (-23.39%)
since 01/07/25
52-Week
60.66 +5.26%
on 04/07/25
Period Open: 125.86
148.15 -56.90%
on 06/25/24
-62.01 (-49.27%)
since 04/05/24

Most Recent Stories

More News
Why Hims & Hers Health Stock Couldn't Beat the Market Today

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous day...

HIMS : 27.10 (+4.27%)
NVO : 62.59 (+0.06%)
LLY : 712.36 (-3.50%)
AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?

AbbVie ABBV stock has gained 16.1% so far this year compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The...

NVO : 62.59 (+0.06%)
LLY : 712.36 (-3.50%)
ABBV : 181.82 (-2.75%)
Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish

The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its investment...

APIE : 26.96 (-2.76%)
NVO : 62.59 (+0.06%)
AVDE : 58.99 (-2.99%)
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?

Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. I'm talking about the weight loss drug market -- one that Morgan Stanley analysts say may multiply by 15...

VKTX : 20.76 (-8.22%)
NVO : 62.59 (+0.06%)
MS : 98.03 (-1.80%)
LLY : 712.36 (-3.50%)
These 2 Mega-Cap Stocks Could Be Even Cheaper Buys Than Nvidia on the Dip

The market appears to be underestimating just how much these two companies can grow.

NVDA : 94.85 (+0.57%)
AAPL : 177.53 (-5.76%)
NVO : 62.59 (+0.06%)
TSM : 143.30 (-2.38%)
DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes

DexCom DXCM recently signed a licensing and data partnership with a privately held healthcare-at-home digital diagnostics company — Nanowear. Per the terms of the agreement, Nanowear will use glucose...

ABT : 122.04 (-1.93%)
NVO : 62.59 (+0.06%)
PODD : 248.76 (+1.43%)
DXCM : 60.06 (+0.38%)
Which Healthcare Stock Is the Best Buy Right Now?

Healthcare stocks provide a combination of upstarts with a high risk, high reward proposition to established firms that can be a defensive maneuver.

VKTX : 20.76 (-8.22%)
NVO : 62.59 (+0.06%)
LLY : 712.36 (-3.50%)
ABSI : 2.21 (-3.07%)
ELV : 418.17 (-2.50%)
Is Hims & Hers Stock Too Cheap to Pass Up?

This high-growth stock may be cheaper than you think.

NVDA : 94.85 (+0.57%)
HIMS : 27.10 (+4.27%)
NVO : 62.59 (+0.06%)
JNJ : 148.16 (-3.32%)
LLY : 712.36 (-3.50%)
Novo Nordisk Stock Slips After BofA, Morgan Stanley Slash Price Targets – But Retail Goes Contrarian

Bank of America analysts said Novo Nordisk might miss first-quarter estimates. According to TheFly, they expect the company to lower its full-year sales guidance from 16%-24% at constant exchange rates...

NVO : 62.59 (+0.06%)
AVDE : 58.99 (-2.99%)
Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?

What goes up can come down. Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain first-hand.

HIMS : 27.10 (+4.27%)
NVO : 62.59 (+0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 67.66
2nd Resistance Point 66.57
1st Resistance Point 64.56
Last Price 62.59
1st Support Level 61.45
2nd Support Level 60.36
3rd Support Level 58.35

See More

52-Week High 148.15
Fibonacci 61.8% 114.73
Fibonacci 50% 104.40
Fibonacci 38.2% 94.08
Last Price 62.59
52-Week Low 60.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.